Business article - January 29, 2026
AstraZeneca plans to invest USD 15 billion in China through 2030
This investment will expand medicines manufacturing and R&D in China and leverage the country’s scientific excellence, advanced manufacturing, and China-UK healthcare ecosystem collaborations.
Business article - January 21, 2026
The first Baltic company joins AstraZeneca BioVentureHub
Lithuanian company Biomatter is an enzyme design company that bridges the gap between generative AI and real-world industrial applications.
Business article - January 14, 2026
JPM 2026: Top Four Business Highlights
This year's JPM business announces include an oncology deal, obesity and radioligand race positioning, and an AI alliance.
Business article - January 9, 2026
PCI Biotech discontinues R&D operations
The company's external evaluation of a new bioprocessing technology has been concluded, with no prospects for further collaboration.
Business article - December 20, 2025
The EU’s new pharmaceutical legislation has been presented
There are welcome improvements but in the major issues around data protection and market exclusivity, the basic conditions for investments in new medicines, the new legislation will unfortunately not strengthen the EU's competitiveness, states SwedenBIO.
Biotech Business - November 18, 2025
Sofinnova announces USD 750M fund that will invest in early stage biotechs
European life science VC firm Sofinnova Partners has announced the close of its latest flagship fund, Sofinnova Capital XI, at EUR 650 million (USD 750 million).
